CFO Nitin Agrawal Resigns, To Be Relieved From 30 September 2026
Alkem's Chief Financial Officer, Mr. Nitin Agrawal, has resigned.
- CFO Name
- Mr. Nitin Agrawal
- Resignation Date
- 30th July, 2026
- Effective Exit Date
- 30th September, 2026
- Reason
- To pursue new professional opportunities
- Transition Period
- From 30th July 2026 to 30th September 2026
What was announced
Alkem Laboratories has disclosed a change in Key Managerial Personnel. Mr. Nitin Agrawal, Chief Financial Officer and Key Managerial Personnel, has resigned.
Key dates
- Resignation tendered on 30th July, 2026.
- He shall cease to hold the Senior Management Position effective 30th September, 2026.
Reason given
The company states the resignation is to pursue new professional opportunities. In his letter to the Chairman, Mr. Agrawal writes that he has chosen to step down to pursue new professional opportunities that align more closely with his long-term professional and personal growth, and that the decision was not an easy one.
Transition
He states he remains fully committed to supporting the management in ensuring a seamless handover of all ongoing strategic initiatives, and will serve through 30 September 2026.
Work referenced in the letter
- Building the MedTech business from the ground up
- The acquisition of Adroit
- The creation of Alkem Wellness
- The formation of the Saudi joint venture
- The acquisition of Bombay Ortho
- Liquidation of idle assets such as the Indore SEZ plant
- Enhancement of rate of returns on treasury income
- Implementation of the new UCPMP marketing guidelines in the domestic market
- Most recently leading the acquisition of Occlutech
What it means for investors
A CFO exit is a senior finance leadership change and is often watched closely by investors, since the CFO oversees financial reporting and capital decisions. The stated reason is personal career progression, and the update records a defined transition period running to end-September 2026.
Also from Alkem Laboratories
Brokerage Amquity upgraded Alkem Laboratories to outperform from underperform and raised target price to 6,000 from 4,900
7 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.